Cargando…

Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis

BACKGROUND: The protein 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) is a key stimulator of glycolytic flux. Systemic, partial PFKFB3 inhibition previously decreased total plaque burden and increased plaque stability. However, it is unclear which cell type conferred these positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Tillie, Renée J. H. A., De Bruijn, Jenny, Perales-Patón, Javier, Temmerman, Lieve, Ghosheh, Yanal, Van Kuijk, Kim, Gijbels, Marion J., Carmeliet, Peter, Ley, Klaus, Saez-Rodriguez, Julio, Sluimer, Judith C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387953/
https://www.ncbi.nlm.nih.gov/pubmed/34458258
http://dx.doi.org/10.3389/fcell.2021.695684
_version_ 1783742549056290816
author Tillie, Renée J. H. A.
De Bruijn, Jenny
Perales-Patón, Javier
Temmerman, Lieve
Ghosheh, Yanal
Van Kuijk, Kim
Gijbels, Marion J.
Carmeliet, Peter
Ley, Klaus
Saez-Rodriguez, Julio
Sluimer, Judith C.
author_facet Tillie, Renée J. H. A.
De Bruijn, Jenny
Perales-Patón, Javier
Temmerman, Lieve
Ghosheh, Yanal
Van Kuijk, Kim
Gijbels, Marion J.
Carmeliet, Peter
Ley, Klaus
Saez-Rodriguez, Julio
Sluimer, Judith C.
author_sort Tillie, Renée J. H. A.
collection PubMed
description BACKGROUND: The protein 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) is a key stimulator of glycolytic flux. Systemic, partial PFKFB3 inhibition previously decreased total plaque burden and increased plaque stability. However, it is unclear which cell type conferred these positive effects. Myeloid cells play an important role in atherogenesis, and mainly rely on glycolysis for energy supply. Thus, we studied whether myeloid inhibition of PFKFB3-mediated glycolysis in Ldlr(–/–)LysMCre(+/–)Pfkfb3(fl/fl) (Pfkfb3(fl/fl)) mice confers beneficial effects on plaque stability and alleviates cardiovascular disease burden compared to Ldlr(–/–)LysMCre(+/–)Pfkfb3(wt/wt) control mice (Pfkfb3(wt/wt)). METHODS AND RESULTS: Analysis of atherosclerotic human and murine single-cell populations confirmed PFKFB3/Pfkfb3 expression in myeloid cells, but also in lymphocytes, endothelial cells, fibroblasts and smooth muscle cells. Pfkfb3(wt/wt) and Pfkfb3(fl/fl) mice were fed a 0.25% cholesterol diet for 12 weeks. Pfkfb3(fl/fl) bone marrow-derived macrophages (BMDMs) showed 50% knockdown of Pfkfb3 mRNA. As expected based on partial glycolysis inhibition, extracellular acidification rate as a measure of glycolysis was partially reduced in Pfkfb3(fl/fl) compared to Pfkfb3(wt/wt) BMDMs. Unexpectedly, plaque and necrotic core size, as well as macrophage (MAC3), neutrophil (Ly6G) and collagen (Sirius Red) content were unchanged in advanced Pfkfb3(fl/fl) lesions. Similarly, early lesion plaque and necrotic core size and total plaque burden were unaffected. CONCLUSION: Partial myeloid knockdown of PFKFB3 did not affect atherosclerosis development in advanced or early lesions. Previously reported positive effects of systemic, partial PFKFB3 inhibition on lesion stabilization, do not seem conferred by monocytes, macrophages or neutrophils. Instead, other Pfkfb3-expressing cells in atherosclerosis might be responsible, such as DCs, smooth muscle cells or fibroblasts.
format Online
Article
Text
id pubmed-8387953
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83879532021-08-27 Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis Tillie, Renée J. H. A. De Bruijn, Jenny Perales-Patón, Javier Temmerman, Lieve Ghosheh, Yanal Van Kuijk, Kim Gijbels, Marion J. Carmeliet, Peter Ley, Klaus Saez-Rodriguez, Julio Sluimer, Judith C. Front Cell Dev Biol Cell and Developmental Biology BACKGROUND: The protein 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) is a key stimulator of glycolytic flux. Systemic, partial PFKFB3 inhibition previously decreased total plaque burden and increased plaque stability. However, it is unclear which cell type conferred these positive effects. Myeloid cells play an important role in atherogenesis, and mainly rely on glycolysis for energy supply. Thus, we studied whether myeloid inhibition of PFKFB3-mediated glycolysis in Ldlr(–/–)LysMCre(+/–)Pfkfb3(fl/fl) (Pfkfb3(fl/fl)) mice confers beneficial effects on plaque stability and alleviates cardiovascular disease burden compared to Ldlr(–/–)LysMCre(+/–)Pfkfb3(wt/wt) control mice (Pfkfb3(wt/wt)). METHODS AND RESULTS: Analysis of atherosclerotic human and murine single-cell populations confirmed PFKFB3/Pfkfb3 expression in myeloid cells, but also in lymphocytes, endothelial cells, fibroblasts and smooth muscle cells. Pfkfb3(wt/wt) and Pfkfb3(fl/fl) mice were fed a 0.25% cholesterol diet for 12 weeks. Pfkfb3(fl/fl) bone marrow-derived macrophages (BMDMs) showed 50% knockdown of Pfkfb3 mRNA. As expected based on partial glycolysis inhibition, extracellular acidification rate as a measure of glycolysis was partially reduced in Pfkfb3(fl/fl) compared to Pfkfb3(wt/wt) BMDMs. Unexpectedly, plaque and necrotic core size, as well as macrophage (MAC3), neutrophil (Ly6G) and collagen (Sirius Red) content were unchanged in advanced Pfkfb3(fl/fl) lesions. Similarly, early lesion plaque and necrotic core size and total plaque burden were unaffected. CONCLUSION: Partial myeloid knockdown of PFKFB3 did not affect atherosclerosis development in advanced or early lesions. Previously reported positive effects of systemic, partial PFKFB3 inhibition on lesion stabilization, do not seem conferred by monocytes, macrophages or neutrophils. Instead, other Pfkfb3-expressing cells in atherosclerosis might be responsible, such as DCs, smooth muscle cells or fibroblasts. Frontiers Media S.A. 2021-08-12 /pmc/articles/PMC8387953/ /pubmed/34458258 http://dx.doi.org/10.3389/fcell.2021.695684 Text en Copyright © 2021 Tillie, De Bruijn, Perales-Patón, Temmerman, Ghosheh, Van Kuijk, Gijbels, Carmeliet, Ley, Saez-Rodriguez and Sluimer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Tillie, Renée J. H. A.
De Bruijn, Jenny
Perales-Patón, Javier
Temmerman, Lieve
Ghosheh, Yanal
Van Kuijk, Kim
Gijbels, Marion J.
Carmeliet, Peter
Ley, Klaus
Saez-Rodriguez, Julio
Sluimer, Judith C.
Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis
title Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis
title_full Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis
title_fullStr Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis
title_full_unstemmed Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis
title_short Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis
title_sort partial inhibition of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (pfkfb3) enzyme in myeloid cells does not affect atherosclerosis
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387953/
https://www.ncbi.nlm.nih.gov/pubmed/34458258
http://dx.doi.org/10.3389/fcell.2021.695684
work_keys_str_mv AT tilliereneejha partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis
AT debruijnjenny partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis
AT peralespatonjavier partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis
AT temmermanlieve partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis
AT ghoshehyanal partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis
AT vankuijkkim partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis
AT gijbelsmarionj partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis
AT carmelietpeter partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis
AT leyklaus partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis
AT saezrodriguezjulio partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis
AT sluimerjudithc partialinhibitionofthe6phosphofructo2kinasefructose26bisphosphatase3pfkfb3enzymeinmyeloidcellsdoesnotaffectatherosclerosis